Profile data is unavailable for this security.
About the company
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
- Revenue in CAD (TTM)0.00
- Net income in CAD-14.07m
- Incorporated2005
- Employees18.00
- LocationResverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
- Phone+1 (403) 254-9252
- Fax+1 (403) 254-9252
- Websitehttps://www.resverlogix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CanadaBis Capital Inc | 20.91m | 3.27m | 11.73m | -- | 3.59 | 1.44 | 2.90 | 0.561 | 0.0237 | 0.0237 | 0.1514 | 0.0592 | 0.9778 | 1.90 | 9.81 | -- | 15.27 | -20.55 | 27.30 | -54.86 | 52.50 | -- | 15.62 | -26.61 | 0.5509 | 7.88 | 0.4948 | -- | 90.44 | -- | 630.61 | -- | 238.08 | -- |
Willow Biosciences Inc | 949.00k | -10.62m | 12.72m | 19.00 | -- | 8.22 | -- | 13.41 | -0.0853 | -0.0853 | 0.0076 | 0.0122 | 0.105 | -- | 3.16 | 49,947.37 | -117.47 | -- | -144.53 | -- | -- | -- | -1,118.76 | -- | 1.29 | -- | 0.5682 | -- | 42.75 | -- | 12.05 | -- | -- | -- |
Resverlogix Corp | 0.00 | -14.07m | 13.74m | 18.00 | -- | -- | -- | -- | -0.0546 | -0.0546 | 0.00 | -0.3657 | 0.00 | -- | -- | 0.00 | -133.25 | -- | -- | -- | -- | -- | -- | -- | 0.0359 | -1.10 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
Hempalta Corp | 251.31k | -974.31k | 14.24m | -- | -- | 2.57 | -- | 56.67 | -0.0177 | -0.0177 | 0.0064 | 0.0584 | 0.0523 | -- | 3.92 | -- | -20.29 | -- | -21.77 | -- | -10.09 | -- | -387.69 | -- | 4.36 | -32.88 | 0.2755 | -- | -- | -- | 113.13 | -- | -- | -- |
Telo Genomics Corp | 0.00 | -2.97m | 14.26m | -- | -- | 23.79 | -- | -- | -0.0434 | -0.0434 | 0.00 | 0.0084 | 0.00 | -- | -- | -- | -323.36 | -85.03 | -407.98 | -113.86 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.66 | -- | 24.41 | -- |
Sirona Biochem Corp | 36.35k | -2.65m | 15.39m | -- | -- | -- | -- | 423.31 | -0.0105 | -0.0105 | 0.0001 | -0.011 | 0.0492 | -- | 7.70 | -- | -358.70 | -173.09 | -- | -383.49 | -- | -- | -7,297.85 | -1,405.28 | -- | -9.04 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
Numinus Wellness Inc | 23.14m | -26.99m | 15.82m | -- | -- | 1.59 | -- | 0.6839 | -0.1022 | -0.1022 | 0.0877 | 0.0315 | 0.7724 | -- | 11.76 | -- | -90.11 | -77.31 | -106.01 | -84.20 | 33.28 | -- | -116.66 | -323.32 | -- | -14.79 | 0.3876 | -- | 256.95 | -- | 32.59 | -- | -- | -- |